Table 2.
Predictor | Univariate model | Multivariate model | ||||
---|---|---|---|---|---|---|
| ||||||
OR | 95% CI | p | OR | 95% CI | p | |
Age at RP, year | 1.01 | 0.97, 1.05 | 0.6 | 1.02 | 0.97, 1.07 | 0.5 |
| ||||||
Pre-RP PSA, ng/mL (n=209) | 0.99 | 0.97, 1.01 | 0.5 | 0.99 | 0.95, 1.03 | 0.6 |
| ||||||
Type of surgery (laparoscopic/robotic vs. open) (n=264) | 2.05 | 1.20, 3.49 | 0.009 | 2.02 | 0.92, 4.44 | 0.08 |
| ||||||
Year of RP, year (n=258) | 1.04 | 0.99, 1.10 | 0.16 | 1.12 | 0.80, 1.55 | 0.5 |
| ||||||
Clinical stage (≤T2A vs ≥T2B) (n=202) | 1.45 | 0.76, 2.78 | 0.3 | 2.27 | 0.86, 5.97 | 0.10 |
| ||||||
Nerve sparing status (n=185) | 0.9 | 0.8 | ||||
No nerves spared | reference | reference | reference | reference | ||
Unilaterally spared | 0.88 | 0.30, 2.55 | 0.83 | 0.32, 2.15 | ||
Bilaterally spared | 0.86 | 0.42, 1.77 | 0.71 | 0.23, 2.14 | ||
| ||||||
Biopsy Gleason grade (n=215) | 0.5 | 0.24 | ||||
≤6 | reference | reference | reference | reference | ||
=7 | 1.07 | 0.59, 1.91 | 1.05 | 0.49, 2.24 | ||
≥8 | 0.60 | 0.24, 1.49 | 0.32 | 0.08, 1.39 | ||
| ||||||
Time between RP and UDS evaluation, per every 6 months (n=258) | 0.98 | 0.95, 1.01 | 0.13 | 1.05 | 0.88, 1.26 | 0.6 |
| ||||||
Pelvic radiation (yes vs. no) (n=264) | 0.77 | 0.41, 1.43 | 0.4 | 2.80 | 0.74, 10.6 | 0.13 |
RP: radical prostatectomy; UDS: urodynamic studies; PSA: prostate-specific antigen ; OR: odds ratio; CI: confidence interval.